Matthew Chersich to Stavudine
This is a "connection" page, showing publications Matthew Chersich has written about Stavudine.
Connection Strength
0,462
-
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. J Acquir Immune Defic Syndr. 2019 02 01; 80(2):224-233.
Score: 0,148
-
Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir. Retrovirology. 2018 12 14; 15(1):77.
Score: 0,147
-
Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. AIDS. 2013 Mar 13; 27(5):781-5.
Score: 0,099
-
Dandy-Walker variant in an infant prenatally exposed to antiretroviral medication. S Afr Med J. 2007 Oct; 97(10):947-8.
Score: 0,068